1/4 Out today from Duke-Margolis/Leavitt Partners in Health Affairs: study of factors influencing #AccountableCareOrganization (ACO) survival in #Medicare's flagship alternative to fee-for-service, #MSSP. @WillBleser David Muhlestein #HealthPolicy bit.ly/2Jl0gYG

Trust = Consistency / Time. Jacob Reider emphasizes how community based orgs have had funding rug pulled out from them time & time again. First step to improving community health is rebuilding this trust. Then partner together to find sustainable roles in value-based arrangements.

We need new drugs and vaccines for diseases faced by people in tropical climates, including soldiers. At the Walter Reed Army Institute of Research (WRAIR), Monika Schneider and David Ridley of Duke-Margolis discussed incentives for companies developing drugs and vaccines.

We really need to learn from replication studies like this. Helps identify when observational #RealWorldEvidence #RWE is fit-for-use. Duke-Margolis amit optumlabs.com/news-events/ne…

Thank you to all of our speakers and to all of you who attended the workshop physically and via webcast! We will be continuing the discussion tomorrow at 9am with key takeaways from today. #RWEregulatory

Blinding might not be necessary if using more objective endpoint, clinical equipoise, larger tx effect, AND for modifying/supplementing the indication #RealWorldEvidence #RWERegulatory

They don’t. Should be trying to measure the most meaningful outcomes from patient perspective. Hopefully those are important for regulators and payers too and can be measured #RealWorldEvidence #RWEregulatory

Totally agree Bray! These techs are the future (and present) for actually efficiently measuring what matters to patients. Should be critical for regulatory and payer decisions.

Ha! He’s great. Such and important topic we’re thrilled to host this important topic #RealWorldEvidence #RWEregulatory

Very important topic. Many opportunities for #RandomisedRWE to leverage vast and high quality #RWD for labeling supplements #RWEregulatory

Dr. Jacqueline Corrigan-Curay U.S. FDA provides the opening remarks at the Improving the Implementation of Risk-Based Monitoring Approaches of Clinical Investigations public workshop

Read the most recent white paper bit.ly/2YlL9pS to learn about how FDA can better ensure drug safety through improved approaches to risk communication. Greg Daniel, PhD Sarah Sheehan Stacie Dusetzina Bernie Good Former Account of Eli Lilly and Company Joseph Ross

Another great discussion table. Glad to reconnect w Greg Daniel now at Edwards Lifesciences n meet Megan Coder from DTXAlliance Need guidance on #ptpreferences mst, transparency on models used in #ValueAssessment #PuttingPatientsFirst National Health Council

Introduce yourself #GoBucks #ToughLove

Stand Up, Stand Out #GoBucks #ToughLove

#COVIDTherapeutics webinar is live We need to identify likely target molecules, streamline testing and approval, scale up manufacturing capacity and improve #RealWorldEvidence for treatments that come to market via accelerated and emergency approval pathways

Challenge of #COVIDTherapeutics early access provisions is that this removes individuals from trials. Including early access into a registry still allows for #RealWorldEvidence generation

Yet another example of how #RWE helps us learn about impact of treatment (this time, possible COVID-19 treatments) as fast as possible, broader populations

In this month's Health Affairs, Duke-Margolis scholars and researchers develop models to pay for value for high cost medical technologies healthaffairs.org/doi/full/10.13…

TOMORROW: Our MDIC's Annual Public Forum continues with a discussion on access and reimbursement including an update on our HEPV initiative! Learn more and register: bit.ly/2KLay3w #MDICAPF2020 Medtronic, Edwards Lifesciences, CMSGov, National Health Council, Blue Cross Blue Shield Association